SCHEMBL586074

SCHEMBL586074

C[C@](N)(Cc1cccc(O)c1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.65
CYP1A2 P05177 4/20 0.64
CYP3A4 P08684 3/20 0.64
ALOX15 P16050 3/20 0.64
KDM4E B2RXH2 3/20 0.64
MAPT P10636 3/20 0.64
PMP22 Q01453 2/20 0.64
KMT2A Q03164 2/20 0.64
ALDH1A1 P00352 2/20 0.64
POLB P06746 2/20 0.64
HPGD P15428 2/20 0.64
HSD17B10 Q99714 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
MEN1 O00255 1/20 0.64
USP2 O75604 1/20 0.64
EGFR P00533 1/20 0.64
FYN P06241 1/20 0.64
GAA P10253 1/20 0.64
APEX1 P27695 1/20 0.64
ADRA1A P35348 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL586073 1.00 BLM (0.65) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL4623745 0.87 BLM (0.47) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL4623739 0.87 BLM (0.47) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL31563007 0.84 GRM2 (0.58) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL6532919 0.83 KDM4E (0.59) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL29053361 0.83 CTBP2 (0.46) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL122296 0.82 BLM (0.72) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL122295 0.82 BLM (0.72) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL202327 0.82 BLM (0.72) BLMCYP1A2CYP3A4ALOX15KDM4E
SCHEMBL6339842 0.82 BLM (0.58) BLMCYP1A2CYP3A4ALOX15KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040101523-A1 Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension G.D. SEARLE & CO. 2004-05-27 US claimed
US-20030220521-A1 Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension G.D. SEARLE & CO. 2003-11-27 US claimed
EP-0484437-A4 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION SEARLE & CO (US) 1994-06-01 EP claimed
EP-0484437-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. Searle & Co. (US) 1992-05-13 EP claimed
WO-1992001667-A1 RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1992-02-06 WO claimed
WO-1991001724-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1991-02-21 WO claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-4230883-A REACTION OF CORRESPONDING AMINO ACID WITH HCL OR HBR IN THE ABSENCE OF A SOLVENT MERCK & CO., INC. (US) 1980-10-28 US claimed
US-20240124496-A1 BORONIC ACID COMPOUND AND METHOD FOR PRODUCING SAME OSAKA UNIVERSITY (JP) 2024-04-18 US disclosed
WO-2024063095-A1 RADIOLABELED TYROSINE DERIVATIVE AND APPLICATION THEREOF 国立大学法人大阪大学 2024-03-28 WO disclosed
CN-117561267-A Boric acid compound and method for producing same 国立大学法人大阪大学 2024-02-13 CN disclosed
EP-4317165-A1 BORONIC ACID COMPOUND AND METHOD FOR PRODUCING SAME OSAKA UNIVERSITY (JP) 2024-02-07 EP disclosed
CN-105073757-B Dyeing process using a hair-dyeing precursor obtained from an iridoid, composition, precursor and device comprising such a precursor 莱雅公司 2019-12-17 CN disclosed
EP-2978749-A1 OPTIONALLY PROTECTED IRIDOID-DERIVED COMPOUNDS, COMPOSITION INCLUDING SAME, USE AS A DYE FOR KERATIN FIBRES AND DEVICES L'Oréal (FR) 2016-02-03 EP disclosed
US-4483870-A α-Difluoromethyl amino acids and hypertension treating compositions thereof MERCK & CO., INC. (US) 1984-11-20 US disclosed
US-4389415-A ALPHA-METHYL-P-TYROSINE, HYDRAZINO PHENYLPROPIONIC ACID MERCK & CO., INC. (US) 1983-06-21 US disclosed
EP-0007600-B1 ALPHA-DIFLUOROMETHYL AMINO ACIDS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MERCK & CO. INC. (US) 1983-05-11 EP disclosed
EP-0007600-A1 Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same MERCK & CO. INC. (US) 1980-02-06 EP disclosed
EP-0003353-A1 A pharmaceutical composition for oral administration for treating hypertension MERCK & CO. INC. (US) 1979-08-08 EP disclosed
US-4117161-A METHOD OF PHARMACOLOGICALLY TREATING DRUG ADDICTION WITH ALPHA-METHYL-PARA-TYROSINE POZUELO JOSE 1978-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124496-A1 BORONIC ACID COMPOUND AND METHOD FOR PRODUCING SAME ABL1, BTD, BMX BLM 2083/4885CYP1A2 704/4885CYP3A4 605/4885
US-20030220521-A1 Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension GLS, APEH, GGH BLM 4877/4885CYP1A2 1710/4885CYP3A4 1387/4885
US-20040101523-A1 Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension GLS, DBH, APEH BLM 4881/4885CYP1A2 2289/4885CYP3A4 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.